Viridian appoints Agios CMO Dr. Sarah Gheuens to Board of Directors

Viridian Therapeutics, Inc.\DE

Board expanded from 5 to 6 directors; Gheuens appointed Class I director until 2025 annual meeting.
Also appointed to Science and Technology Committee.
Compensation: $46,000 annual retainer and option for 40,000 shares vesting over 3 years.
Gheuens is CMO of Agios Pharmaceuticals (AGIO) and previously held roles at Biogen (BIIB).
No arrangements, family relationships, or material interests requiring disclosure.

item 5.02

Executive movements

Machine-extracted from this filing. Every card cites the SEC source. See all recent executive movements.

Appointed

Sarah Gheuens

Director

VRDN · Viridian Therapeutics, Inc.\DE

Effective: 2023-09-21
Filed: September 25, 2023, 7:59 PM ET

Effective September 21, 2023, the Board of Directors (the “Board”) of Viridian Therapeutics, Inc. (the “Company”) increased the size of the Board from five to six directors and appointed a new director, Dr. Sarah Gheuens, to serve as a Class I director to hold office until the 2025 Annual Meeting of Stockholders and until her successor shall have been duly elected and qualified.

Key facts

Extracted from this filing and checked against the source text.

Executive change SEC 8-K Item 5.02 confidence 0.95

Sarah Gheuens was appointed as Director at Viridian Therapeutics, Inc.\DE.

Action: appointed
Role: Director

Exact text from the filing

Effective September 21, 2023, the Board of Directors (the “Board”) of Viridian Therapeutics, Inc. (the “Company”) increased the size of the Board from five to six directors and appointed a new director, Dr. Sarah Gheuens, to serve as a Class I director to hold office until the 2025 Annual Meeting of Stockholders and until her successor shall have been duly elected and qualified.

View on SEC.gov

Viridian Therapeutics, Inc.\DE filing history →

Source: SEC EDGAR

accession 0001193125-23-240931

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.